| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 02/26/2004 | WO2002087419A3 Biological pacemaker |
| 02/26/2004 | WO2002085290A3 Edg : modulators of lymphocyte activation and migration |
| 02/26/2004 | WO2002083917A8 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer |
| 02/26/2004 | WO2002079472A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 02/26/2004 | WO2002077227A3 Iterative optimization in the design of binding proteins |
| 02/26/2004 | WO2002074921A3 Methods for isolating proteins expressed by dendritic cells |
| 02/26/2004 | WO2002074809A3 Zinc-sensing receptor and methods of treatment of disorders associated herewith |
| 02/26/2004 | WO2002074808A3 Modified insulin with reduced immunogenicity |
| 02/26/2004 | WO2002074793A3 Novel peptides for the diagnosis of schizophrenia |
| 02/26/2004 | WO2002070705A3 Human 7tm proteins and polynucleotides encoding them |
| 02/26/2004 | WO2002068600A3 Endogenous and non-endogenous versions of human g protein-coupled receptors |
| 02/26/2004 | WO2002067982A3 Mycobacterial vaccines |
| 02/26/2004 | WO2002066652A3 Ehrlichia ruminantium polypeptides, antigens, polynucleotides, and methods of use |
| 02/26/2004 | WO2002062204A3 Methods for diagnosing and treating heart disease |
| 02/26/2004 | WO2002059345A3 Nucleic acid encoding ion transporter component protein |
| 02/26/2004 | WO2002059263A3 Transgenic animals comprising a humanized immune system |
| 02/26/2004 | WO2002056701A3 Gelling vegetable protein |
| 02/26/2004 | WO2002051237A3 Helicobacter proteins, nucleic acids and uses thereof |
| 02/26/2004 | WO2002050277A3 Protein and nucleic acids encoding same |
| 02/26/2004 | WO2002048369A3 Polynucleotide encoding a human potassium channel beta-subunit, k+mbeta1 |
| 02/26/2004 | WO2002048345A3 Transgenic mice containing glutamate receptor (grik5) gene disruptions |
| 02/26/2004 | WO2002046418A3 Lipid-associated molecules |
| 02/26/2004 | WO2002045498A3 Transgenic mice containing channel protein target gene disruptions |
| 02/26/2004 | WO2002045496A3 Transenic mice containing frp-rs4 gene disruptions |
| 02/26/2004 | WO2002045494A3 Transgenic mice containing glucagon receptor gene disruptions |
| 02/26/2004 | WO2002045492A3 Transgenic mice containing polycystin-related gene disruptions |
| 02/26/2004 | WO2002042487A3 Compositions, methods and kits relating to remodelin |
| 02/26/2004 | WO2002042424A3 Seed-preferred regulatory elements and uses thereof |
| 02/26/2004 | WO2002042420A3 Modulation of gene expression during intimal hyperplasia of the carotid artery |
| 02/26/2004 | WO2002042336A3 Fgf-affinity chromatography |
| 02/26/2004 | WO2002040656A3 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, and 84234, novel human guanine nucleotide dissociation stimulator, glycosyltransferase, dead type helicase, centaurin, dehydrogenase/reductase, and metal transporter family members and uses thereof |
| 02/26/2004 | WO2002040542A3 58569 and 50111, human anion exchange proteins and methods of use thereof |
| 02/26/2004 | WO2002038796A3 Methods for determining protease cleavage site motifs |
| 02/26/2004 | WO2002038765A3 Dna encoding bovine immunoglobulin a inducing protein and uses therefor |
| 02/26/2004 | WO2002034782A3 Endozepine-like polypeptide nov1 and nucleic acid encoding the same |
| 02/26/2004 | WO2002033089A3 Ixodes scapularis tissue factor pathway inhibitor |
| 02/26/2004 | WO2002031152A3 Intracellular signaling molecules |
| 02/26/2004 | WO2002028873A3 Transcription factor polynucleotides, polypeptides, antibodies, and methods based thereon |
| 02/26/2004 | WO2002006480A3 Tissue inhibitors of matrix metalloproteinases |
| 02/26/2004 | WO2001088192A3 A method for generating hypermutable organisms |
| 02/26/2004 | WO2001074299A3 Compositions and methods for inhibition of cancer invasion and angiogenesis |
| 02/26/2004 | WO2001066723A3 Hetero-oligomeric g protein-coupled receptors as drug target |
| 02/26/2004 | WO2001057175A3 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 02/26/2004 | US20040040062 Method for producing human lactoferrin in plant cell culture |
| 02/26/2004 | US20040040061 Corn for administration to animals to elicit immune respone; plant extracts |
| 02/26/2004 | US20040040059 Pectinophora gossypiella (pink bollworm) bacillus thuringiensis toxin receptor BT-R2 |
| 02/26/2004 | US20040040057 Plant Myb transcription factor homologs |
| 02/26/2004 | US20040040054 Modifying the expression of a Na+/H+ antiporter coding nucleic acid in the plant ,wherein the plant has an increased tolerance to an environmental stress as compared to a wild type variety of the plant; genetic engineering |
| 02/26/2004 | US20040040049 Reduction in the formation of the complex in the presence of the candidate agent as compared with in the absence of candidate agent indicates the candidate agent inhibits the binding of LBP-2 to the LBP-2 binding molecule |
| 02/26/2004 | US20040040045 Method of screening for substance preventing or treating diseases in association with malfunction of il-6 family cytokine receptor malfunction |
| 02/26/2004 | US20040039187 Chimeric GB virus B (GBV-B) |
| 02/26/2004 | US20040039186 Self-regulated apoptosis of inflammatory cells by gene therapy |
| 02/26/2004 | US20040039185 Novel family member of inhibitor of apoptosis proteins |
| 02/26/2004 | US20040039184 Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
| 02/26/2004 | US20040039179 Lithography; ink jet printing; for drug delivery |
| 02/26/2004 | US20040039178 Metal chelate-labelled peptides |
| 02/26/2004 | US20040039175 Comprises HIV/herpes virus promoter sequence |
| 02/26/2004 | US20040039173 G-protein-coupled receptor proteins characterized by having sufficient binding affinity for corticotropin releasing factor(CRF) such that concentrations of # 10 nM of CRF occupy 350% of the binding sites of said receptor protein |
| 02/26/2004 | US20040039172 Relates to immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates and method of inducing anti-HIV antibodies using such immunogen |
| 02/26/2004 | US20040039170 Regulation of human g protein-coupled receptor |
| 02/26/2004 | US20040039169 BASB202 polypeptides and polynucleotides encoding BASB202 polypeptides and methods for producing such polypeptides by recombinant techniques; diagnostic, prophylactic and therapeutic uses |
| 02/26/2004 | US20040039168 Staged assembly process for nanometer-sized peptide structures useful in construction of microscopic and macroscopic structures; sequentially adding individual building blocks to growing structure to build nanostructure |
| 02/26/2004 | US20040039167 Derivatives of maurotoxin and of particular toxins belonging to the same structural class of K+ channel-acting short-chain scorpion toxins (less than 40 amino acid residues) that are cross-linked by four disulfide bridges; nerve disorder therapy |
| 02/26/2004 | US20040039166 Newly identified polypeptides and polynucleotides encoding such polypeptides referred to as inhibitor of apoptosis proteins (IAPL-3); use in diagnosis and in identifying compounds that may be agonists, antagonists |
| 02/26/2004 | US20040039165 Clostridium difficile polypeptides and uses thereof |
| 02/26/2004 | US20040039164 Invention relates to identification and isolation of novel DNA and to recombinant production of novel polypeptides |
| 02/26/2004 | US20040039163 Methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins |
| 02/26/2004 | US20040039162 Gdf-1 |
| 02/26/2004 | US20040039157 Derived from fibrinogen; gene therapy; animal models |
| 02/26/2004 | US20040039156 Comprises fusion proteins isolated from influenza virus hemagglutinin and colony stimulating factor |
| 02/26/2004 | US20040038924 Adenovirus serotype 30 (Ad30) |
| 02/26/2004 | US20040038920 Which stimulate lymphoctyes specific for myelin basic protein (MBP) autoantigen, which induces severe experimental autoimmune encephalomyelitis in animal models; cytokines |
| 02/26/2004 | US20040038918 Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy |
| 02/26/2004 | US20040038917 Such as urinary bladder tissue; immunoassays |
| 02/26/2004 | US20040038902 For therapy of neoplastic disease |
| 02/26/2004 | US20040038901 Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon |
| 02/26/2004 | US20040038900 For therapy of diabetes and other insulin-requiring states, hypoglycemia |
| 02/26/2004 | US20040038897 Stimulates a sexual and/or erectile response in a mammal |
| 02/26/2004 | US20040038895 For diagnosis and therapy of respiratory and inflammatory diseases |
| 02/26/2004 | US20040038894 Useful for modulating an animal cell function involved in a disease selected from immunoproliferative diseases, immunodeficiency diseases, cancers, autoimmune diseases, infectious diseases, viral diseases, inflammatory response |
| 02/26/2004 | US20040038893 Prevention and reduction of blood loss |
| 02/26/2004 | US20040038892 Chemically-modified human growth hormone conjugates |
| 02/26/2004 | US20040038890 Human voltage-gated potassium channel subunit |
| 02/26/2004 | US20040038889 Fumaric acid amides |
| 02/26/2004 | US20040038887 Copolymers for suppression of autoimmune diseases, and methods of use |
| 02/26/2004 | US20040038886 Chimeric cytoplasmic signalling molecules derived from cd137 |
| 02/26/2004 | US20040038883 To induce apoptosis in cells and sensitize tumor cells to cancer therapies |
| 02/26/2004 | US20040038880 Brain associated inhibitor of tissue - type plasminogen activator |
| 02/26/2004 | US20040038879 For therapy and prophylaxis of infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure |
| 02/26/2004 | US20040038877 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/26/2004 | US20040038876 For use in therapy and diagnosis |
| 02/26/2004 | US20040038873 Used for the manufacture of medicine for the treatment of developmental disorders, diseases caused by abnormal metabolism of immune system, and cancers |
| 02/26/2004 | US20040038869 Inhibitors of complement activation, their preparation and use |
| 02/26/2004 | US20040038855 Administering a compound which is a mammalian MCH1 receptor antagonist effective to treat the abnormality |
| 02/26/2004 | US20040038430 Monoclonal antibodies specific for PHF-TAU, hybridomas secreting them, antigen recognition by these antibodies and their applications |
| 02/26/2004 | US20040038404 Comprises deletion in adenovirus-2 early region 1A gene; for expression of a protein effective in regulating the cell cycle (such as p53, mitosin, or thymidine kinase suicide genes); tumor suppressor genes/proteins |
| 02/26/2004 | US20040038402 Gene therapy; for production of transgenic animal models |
| 02/26/2004 | US20040038394 Expression vector using for animal cell |
| 02/26/2004 | US20040038381 Comprises genetically engineered strains of Pichia; mannosidases; glycoproteins; kits |
| 02/26/2004 | US20040038379 Probiotic strains from Lactobacillus salivarius and antimicrobial agents obtained therefrom |